This article is more than 5 years old. Information may no longer be current.
Top stories in endocrinology: Patch measures cortisol in sweat, FDA clears first glucose meter
Click Here to Manage Email Alerts
Among the top stories in endocrinology this week was the development of a wearable patch that measures how much cortisol a person is producing through sweat.
Other top stories include the FDA clearance of the first glucose meter for critically ill patients, research findings that lifestyle changes are necessary for mitigating cardiometabolic risk, the recommendation that PCPs and cardiologists consider GLP1 agents for patients with diabetes and cardiovascular disease, and the impact of HbA1c on risk for diabetic polyneuropathy.
Wearable patch measures cortisol in sweat
Researchers from Stanford University have designed a wearable device that measures how much cortisol a person is producing through sweat, according to a press release from the university. Read more.
FDA clears first glucose meter for critically ill patients
The FDA has granted 510(k) clearance for the first finger-stick capillary testing meter for critically ill patients with and without diabetes, Nova Biomedical announced in a press release. Read more.
Lifestyle changes necessary for mitigating cardiometabolic risk
Lifestyle modifications, such as adherence to a healthy diet, smoking cessation and adequate exercise, are a must to help reduce cardiometabolic disease risk, according to a presenter at Heart in Diabetes. Read more.
Cardiologists should consider prescribing GLP1 agents for CVD prevention in type 2 diabetes
Although endocrinologists may routinely prescribe the newer classes of diabetes drugs approved for cardiovascular risk reduction, cardiologists and primary care providers should also consider using these agents for patients with type 2 diabetes and heart disease, according to a speaker at Heart in Diabetes. Read more.
Rate of HbA1c increase influences risk for diabetic polyneuropathy
Among adults with type 2 diabetes, small increases in HbA1c have significant impacts on the risk for diabetic polyneuropathy , according to data from the ADDITION-Denmark study published in Diabetes Care. Read more.